Jessica Rose Darling N.P.

Recommended Articles

• When Should I Get Checked for Prostate Cancer?

  Prostate cancer is more likely to occur in men aged between forty and seventy years old. It is, therefore, important that you should always be on alert in case any symptoms begin to show. This prompts a visit to the doctor within the quickest possible time.Deciding on whether or not to be screened...

• What Are the Symptoms and Treatment Options for Scalp Psoriasis?

  Scalp psoriasis is a very common scalp condition characterized by raised, scaly patches on the scalp. This condition is found in approximately 7.5 million people in the country. In most cases, people with this condition may also have symptoms of psoriasis in other parts of the body. The scalp...

• Spine Doctors vs. Chiropractors

  Patients may often ask themselves which doctor they should see for their back pain. Studies have shown that chiropractors provide effective treatment for back pain. However, chiropractors cannot treat all causes of back pain because there are also conditions that should be diagnosed and treated by a...

• What Is Pituitary Dwarfism?

  IntroductionPituitary dwarfism, also called growth hormone deficiency, is a medical condition wherein the pituitary gland does not produce sufficient amounts of growth hormone. This deficiency often results in children’s slow growth or short stature.An adult with pituitary dwarfism has an average...

• What is Autistic Disorder

  Autistic disorder is defined as the most severe type of autistic spectrum disorder (ASD). It is also called classic autism or Kanner’s Syndrome. This developmental disorder is characterized by challenges with communication, social interaction, and behavior. Autistic people often avoid interaction...

• FDA Approves Baricitinib for Adults with Active Rheumatoid Arthritis

  On June 1st of 2018, the US Food and Drug Administration (FDA) approved Olumiant (Baricitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more TNF inhibitor therapies. “We are pleased to provide RA...